Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Часто задаваемые вопросы
В каком секторе работает Alpha Cognition Inc (ACOGF)?
Alpha Cognition Inc относится к сектору Здравоохранение.
Выплачивает ли Alpha Cognition Inc (ACOGF) дивиденды?
Нет, Alpha Cognition Inc не выплачивает дивиденды.